Tonix Pharmaceuticals Holding (TNXP) 10-K2016 FY Annual report

Filed: 13 Apr 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: abbreviated, acetylcholine, adaptive, advice, affinity, Affordable, agricultural, Agriculture, Alberta, allosteric, amnesia, ANDA, Ankara, anthrax, Antianxiety, antipsychotic, antiviral, anxiolytic, Arestvy, Asia, ATM, attenuate, Bavarian, biomedical, BioShield, biosimilar, botulism, BPCIA, Brainsway, brexpiprazole, brincidofovir, broader, burning, cell, Century, CFR, chimeric, classic, clearance, clinician, CMC, condensed, confirm, confirming, conflated, conventional, corticosteroid, countermeasure, criterion, crossover, crystal, culture, Dawson, DEA, decade, deep, distance, downstream, dual, entrance, equine, eradicated, excessive, exited, exiting, experimental, explicitly, fed, footnote, forfeited, fractional, Glossodynia, glutamatergic, gold, hallucinogen, hereof, Homeland, horsepox, HPXV, hypoaesthesia, IDMC, immunization, Imputation, inappropriately, interchangeable, interview, ion, jointly, Latin, legitimate, lethal, Likewise, magnetic, mannitol, MDMA, methylenedioxymethamphetamine, MI, mice, misapplied, MMRM, monotherapy, MOR, Multidisciplinary, MVA, neurochemical, neurocognitive, neuroplastic, neurotransmitter, nicotinic, Nordic, Noyce, nuclear, occupied, OnApril, organizational, overallotment, oxalate, pace, paresthesia, passage, payor, polymorph, pox, predominantly, procure, PSTD, Psychedelic, psychotherapy, radiological, ratifying, ready, reauthorize, reauthorized, repeal, rescind, respiratory, retrograde, revealed, Rexulti, riluzole, RLD, rolling, routine, RSU, Ryan, safeguarding, salt, SAR, sedation, sensation, sequence, shift, SIGA, skin, sodium, solid, somatic, somnolence, SRF, steroid, stimulation, stinging, stockpile, stockpiling, Subpart, synthetic, tecovirimat, thealpha, tianeptine, tingling, topline, tract, traditional, transcranial, tricyclic, true, Trump, tularemia, unblinded, underway, Uniformed, upcoming, upper, usage, user, variola, viral, virtue, virulence, voucher, Wassenaar

Removed: acceptability, accounted, acted, age, al, Allergan, American, Amital, announced, assuring, Aug, began, Bruce, calcium, career, CEO, chairman, Cohen, College, consisting, Conversely, correspondingly, counterpart, Cymbalta, databank, Daugherty, denied, diagnosed, diminished, dinner, disrupted, disturbance, duloxetine, durable, education, Eli, ETTH, exacerbate, exclusive, family, FDAAA, feature, female, FM, fold, Forest, Foundation, founder, fulfillment, function, gabapentin, Gershell, head, identification, Impression, improving, incremental, irritability, isolation, isomer, isometheptene, led, Leder, leisure, Leland, Lilly, liquidity, long, Lundbeck, Lyrica, mandate, margin, MD, Meda, memory, milnacipran, Moldofsky, monetary, mood, numeric, OTCQB, pain, peak, permanent, PhD, physician, placement, Plumbline, poor, pregabalin, prepare, presently, promissory, Psychosom, purified, radio, ratably, Rating, rationale, reflecting, registry, renew, repaid, Rheum, Rheumatology, RiboCor, Savella, secondary, sedative, Semin, serve, serving, setting, sharing, Starling, subscription, successive, suffering, survey, symptomatic, Theravance, thousand, threshold, tramadol, twelve, unexercised, venlafaxine, violate, VLD, waiver, week

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

TNXP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.01

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Seth Lederman, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Tonix Pharmaceuticals Holding Corp. on Form 10-K for the fiscal year ended December 31, 2016 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of Tonix Pharmaceuticals Holding Corp.

	By:	/s/ SETH LEDERMAN
Date: April 13, 2017	Name:	Seth Lederman
	Title:	Chief Executive Officer

I, Bradley Saenger, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Tonix Pharmaceuticals Holding Corp. on Form 10-K for the fiscal year ended December 31, 2016 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of Tonix Pharmaceuticals Holding Corp.

	By:	/s/ BRADLEY SAENGER
Date: April 13, 2017	Name:	Bradley Saenger
	Title:	Chief Financial Officer